home / stock / xrtx:cc / xrtx:cc quote
Last: | $2.30 |
---|---|
Change Percent: | 6.48% |
Open: | $2.22 |
Close: | $2.30 |
High: | $2.36 |
Low: | $2.17 |
Volume: | 12,565 |
Last Trade Date Time: | 05/06/2022 04:56:49 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.3 | $2.22 | $2.3 | $2.36 | $2.17 | 12,565 | 05-06-2022 |
$2.16 | $2.15 | $2.16 | $2.47 | $2.15 | 36,835 | 05-05-2022 |
$1.95 | $2.1 | $1.95 | $2.2 | $1.85 | 33,865 | 05-04-2022 |
$2.21 | $1.77 | $2.21 | $2.88 | $1.71 | 176,843 | 05-03-2022 |
$1.51 | $1.65 | $1.51 | $1.65 | $1.5 | 20,804 | 05-02-2022 |
$1.65 | $1.78 | $1.65 | $1.83 | $1.65 | 11,788 | 04-29-2022 |
$1.76 | $1.94 | $1.76 | $2.19 | $1.76 | 6,879 | 04-28-2022 |
$1.92 | $1.98 | $1.92 | $2.09 | $1.9 | 15,211 | 04-27-2022 |
$2.01 | $2.2 | $2.01 | $2.2 | $1.91 | 24,038 | 04-26-2022 |
$2.17 | $2.2 | $2.17 | $2.3 | $2.17 | 4,745 | 04-25-2022 |
$2.26 | $2.3 | $2.26 | $2.35 | $2.26 | 5,882 | 04-22-2022 |
$2.34 | $2.5 | $2.34 | $2.5 | $2.34 | 16,732 | 04-21-2022 |
$2.47 | $2.44 | $2.47 | $2.47 | $2.39 | 2,730 | 04-20-2022 |
$2.4 | $2.4 | $2.4 | $2.5 | $2.4 | 14,627 | 04-19-2022 |
$2.39 | $2.4 | $2.39 | $2.4 | $2.39 | 913 | 04-18-2022 |
$2.4 | $2.4 | $2.4 | $2.4 | $2.35 | 7,900 | 04-15-2022 |
$2.4 | $2.4 | $2.4 | $2.4 | $2.35 | 7,900 | 04-14-2022 |
$2.38 | $2.4 | $2.38 | $2.59 | $2.38 | 30,410 | 04-13-2022 |
$2.36 | $2.4 | $2.36 | $2.44 | $2.35 | 14,597 | 04-12-2022 |
$2.43 | $2.44 | $2.43 | $2.45 | $2.43 | 5,035 | 04-11-2022 |
News, Short Squeeze, Breakout and More Instantly...
Xortx Therapeutics Inc. Company Name:
XRTX:CC Stock Symbol:
TSXVC Market:
CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney d...
Malibu, CA, United States (ABN Newswire) - In this segment of Money Talk Radio with Ellis Martin, we speak with Dr. Allen Davidoff, CEO of XORTX Therapeutics (NASDAQ:XRTX) (CVE:XRTX), a pioneer in developing new therapies for progressive kidney disease and diabetes. Recently Vertex Pharmaceut...
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive...